Use of angiotensin receptor – neprilysin inhibitors in heart failure: a paradigm shift
Heart failure is a clinical syndrome responsible for at least one-third of hospitalisations amongst cardiac patients, with escalating mortality and healthcare costs on both public and private health care. Both prevalence and incidence of heart failure increase steeply with advancing age, making it a...
Enregistré dans:
Auteurs principaux: | M. O.E. Irhuma, M. Vally |
---|---|
Format: | article |
Langue: | EN |
Publié: |
AOSIS
2016
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/801839061dbb4212a01f2e4dfd12d184 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Cardiovascular Outcomes with Sacubitril-Valsartan in Heart Failure: Emerging Clinical Data
par: Cuthbert JJ, et autres
Publié: (2020) -
Reply to Siniorakis et al., “COVID-19 Interference with Renin-Angiotensin System in the Context of Heart Failure”
par: David S. Fedson, et autres
Publié: (2020) -
Recent and Upcoming Drug Therapies for Pediatric Heart Failure
par: Karla L. Loss, et autres
Publié: (2021) -
Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review
par: Domingo Pascual-Figal, et autres
Publié: (2021) -
Effect of Angiotensin–Neprilysin Versus Renin–Angiotensin System Inhibition on Renal Outcomes: A Systematic Review and Meta-Analysis
par: Ying Xu, et autres
Publié: (2021)